These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 29301757

  • 21. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.
    Mohler ER, Herrington D, Ouyang P, Mangano C, Ritter S, Davis P, Purkayastha D, Gatlin M, Vogel RA, EXPLORE Investigators.
    J Clin Hypertens (Greenwich); 2006 Oct; 8(10):692-8. PubMed ID: 17028482
    [Abstract] [Full Text] [Related]

  • 22. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, ALLHAT Collaborative Research Group.
    Arch Intern Med; 2006 Nov 13; 166(20):2191-201. PubMed ID: 17101936
    [Abstract] [Full Text] [Related]

  • 23. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
    Riva N, Lip GY.
    Curr Pharm Des; 2013 Nov 13; 19(21):3753-65. PubMed ID: 23286431
    [Abstract] [Full Text] [Related]

  • 24. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ, CONVINCE Research Group.
    JAMA; 2013 Nov 13; 289(16):2073-82. PubMed ID: 12709465
    [Abstract] [Full Text] [Related]

  • 25. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
    Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B.
    Lancet; 2013 Feb 16; 381(9866):537-45. PubMed ID: 23219284
    [Abstract] [Full Text] [Related]

  • 26. [The ACCOMPLISH trial: are results really unexpected?].
    Waeber B, Feihl F.
    Rev Med Suisse; 2009 Jan 07; 5(185):25-8. PubMed ID: 19216321
    [Abstract] [Full Text] [Related]

  • 27. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.
    Byrd JB, Bakris G, Jamerson K.
    Curr Hypertens Rep; 2014 Mar 07; 16(3):419. PubMed ID: 24474031
    [Abstract] [Full Text] [Related]

  • 28. ACCOMPLISH the goal: hypertension and beyond.
    Siragy HM.
    Curr Hypertens Rep; 2009 Aug 07; 11(4):231-2. PubMed ID: 19602321
    [No Abstract] [Full Text] [Related]

  • 29. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy.
    Taylor AA, Shoheiber O.
    Congest Heart Fail; 2003 Aug 07; 9(6):324-32. PubMed ID: 14688505
    [Abstract] [Full Text] [Related]

  • 30. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 31. Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
    Strauss MH, Weinstein J, Newton GE.
    N Engl J Med; 2009 Mar 12; 360(11):1148; author reply 1149-50. PubMed ID: 19283888
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE, Reyes AP, Wurdeman RL, Faulkner M.
    J Hum Hypertens; 2001 Aug 12; 15(8):559-65. PubMed ID: 11494095
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM.
    Clin Drug Investig; 2010 Aug 12; 30(9):625-41. PubMed ID: 20626210
    [Abstract] [Full Text] [Related]

  • 34. Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
    Parra D, Rosenstein R.
    N Engl J Med; 2009 Mar 12; 360(11):1147-8; author reply 1149-50. PubMed ID: 19279348
    [No Abstract] [Full Text] [Related]

  • 35. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES, Fernandes LAB, Giollo-Júnior LT, Uyemura JRR, Matarucco CSS, Landim MIP, Cosenso-Martin LN, Tácito LHB, Moreno H, Vilela-Martin JF, Yugar-Toledo JC.
    Trials; 2018 Feb 12; 19(1):101. PubMed ID: 29433578
    [Abstract] [Full Text] [Related]

  • 36. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo.
    Kuschnir E, Acuña E, Sevilla D, Vasquez J, Bendersky M, Resk J, Glazer R.
    Clin Ther; 1996 Feb 12; 18(6):1213-24. PubMed ID: 9001838
    [Abstract] [Full Text] [Related]

  • 37. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
    Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators.
    Lancet; 1996 Feb 12; 366(9489):895-906. PubMed ID: 16154016
    [Abstract] [Full Text] [Related]

  • 38. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
    Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB, ALLHAT Collaborative Research Group.
    JAMA; 2005 Apr 06; 293(13):1595-608. PubMed ID: 15811979
    [Abstract] [Full Text] [Related]

  • 39. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.
    Hypertension; 2007 Feb 06; 49(2):276-84. PubMed ID: 17159081
    [Abstract] [Full Text] [Related]

  • 40. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
    Chaugai S, Sherpa LY, Sepehry AA, Kerman SRJ, Arima H.
    J Cardiovasc Pharmacol Ther; 2018 Sep 06; 23(5):433-445. PubMed ID: 29739234
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.